Quick Answer
Enliven Therapeutics, Inc. reported Earnings Per Share Diluted of $1.83 (loss) per share for the year ending 2025.
- Enliven Therapeutics, Inc. showed an increase of +3.2% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Enliven Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 5 years of available data (2021 to 2025), Enliven Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 22.8%.
- Historical annual values: Fiscal year 2025: $1.83 (loss) per share | Fiscal year 2024: $1.89 (loss) per share | Fiscal year 2023: $2.01 (loss) per share | Fiscal year 2022: $12.05 (loss) per share | Fiscal year 2021: $2.37 (loss) per share.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: